In this section we usually present revenue and earnings growth
projections based on the consensus estimates of professional
analysts to help investors understand the company’s ability to
generate profit. But as Sam-A Pharm has not provided enough
past data and has no analyst forecast, its future earnings
cannot be reliably calculated by extrapolating past data or
using analyst predictions.
This is quite a rare situation as 97% of companies covered by
SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
KOSDAQ:A009300 - Analysts future estimates and past financials data (KRW Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
3/31/2026
70,928
8,887
7,847
9,722
N/A
12/31/2025
77,799
12,940
8,995
10,723
N/A
9/30/2025
76,659
13,187
9,408
11,620
N/A
6/30/2025
82,518
15,344
14,623
18,157
N/A
3/31/2025
90,126
19,000
16,072
20,793
N/A
12/31/2024
95,581
22,080
18,844
25,247
N/A
9/30/2024
101,393
22,768
25,827
32,527
N/A
6/30/2024
102,550
24,744
24,655
30,253
N/A
3/31/2024
102,511
23,936
25,294
30,074
N/A
12/31/2023
97,211
21,374
17,204
20,760
N/A
9/30/2023
95,931
20,338
16,342
18,144
N/A
6/30/2023
95,324
20,387
15,492
15,844
N/A
3/31/2023
87,159
15,531
17,967
17,536
N/A
12/31/2022
81,700
11,912
20,465
19,604
N/A
9/30/2022
75,479
11,029
17,431
15,629
N/A
6/30/2022
66,172
7,520
17,817
16,940
N/A
3/31/2022
63,638
7,000
13,683
12,874
N/A
12/31/2021
54,666
3,392
13,717
12,943
N/A
9/30/2021
50,907
178
14,005
13,670
N/A
6/30/2021
50,870
-1,115
9,148
9,078
N/A
3/31/2021
48,548
-1,650
9,937
10,177
N/A
12/31/2020
53,653
124
9,056
9,408
N/A
9/30/2020
59,775
3,392
10,004
9,389
N/A
6/30/2020
64,025
5,986
14,968
14,092
N/A
3/31/2020
70,346
9,128
14,889
13,867
N/A
12/31/2019
71,560
10,197
N/A
13,221
N/A
9/30/2019
70,715
9,807
N/A
14,334
N/A
12/31/2018
66,947
8,801
N/A
12,755
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if A009300's forecast earnings growth is above the savings rate (3.1%).
Earnings vs Market: Insufficient data to determine if A009300's earnings are forecast to grow faster than the KR market
High Growth Earnings: Insufficient data to determine if A009300's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if A009300's revenue is forecast to grow faster than the KR market.
High Growth Revenue: Insufficient data to determine if A009300's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if A009300's Return on Equity is forecast to be high in 3 years time
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/15 13:03
End of Day Share Price
2026/07/15 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sam-A Pharm. Co., Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.